Evidence map›Paper›PMID 42642381›Full record

ArticleNature communications2026

Microbiome signatures for detection of colorectal lesions in population-based FIT screening.

Einar E Birkeland, Ane S Kværner, Ekaterina Avershina, Cecilie Bucher-Johannessen, Vahid Bemanian, Hege S Blix, Anette Hjartåker, Willem M de Vos, Giske Ursin, Geir Hoff and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Einar E BirkelandDepartment of Pharmacy, University of Oslo, Oslo, Norway. einareb@uio.no.ORCID http://orcid.org/0000-0002-9361-7987
Ane S KværnerDepartment of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Ekaterina AvershinaDepartment of Pharmacy, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-9935-2804
Cecilie Bucher-JohannessenDepartment of Pharmacy, University of Oslo, Oslo, Norway.
Vahid BemanianDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway.
Hege S BlixDepartment of Pharmacy, University of Oslo, Oslo, Norway.
Anette HjartåkerDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Willem M de VosHuman Microbiome Research Programme, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0273-3166
Giske UrsinDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Geir HoffDepartment of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Kristin R RandelDepartment of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Edoardo BotteriCancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Paula BerstadDepartment of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.ORCID http://orcid.org/0000-0002-9025-4455
Trine B RoungeDepartment of Pharmacy, University of Oslo, Oslo, Norway. trinro@uio.no.ORCID http://orcid.org/0000-0003-2677-2722

Funding

Kreftforeningen (Norwegian Cancer Society) 190179Kreftforeningen (Norwegian Cancer Society) 198048Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2020056
6 · The paper itself

Abstract

The gut microbiome has been linked to colorectal cancer (CRC) development, with microbe-based classifiers distinguishing between CRC patients and healthy controls. However, there is a lack of studies addressing the utility of the microbiome in screening-relevant settings, including both precancers and CRC. In this Norwegian population-based study, we used fecal immunochemical test (FIT) leftovers from 1034 FIT-positive (i.e. positive for occult blood) screening participants for gut metagenome profiling using shotgun sequencing. Using comprehensive clinical, demographic, and lifestyle data, we modeled gut microbiome associations with CRC screening outcomes. Combining microbial profiles with quantitative FIT values improved detection of premalignant lesions beyond optimizing the FIT value alone, even after incorporating established CRC risk factors. Still, the FIT value maintained superior discriminative ability for CRC. We confirmed enrichment of bacteria such as Fusobacterium nucleatum and Peptostreptococcus stomatis in CRC. In contrast, other bacteria previously associated with the presence of CRC, including Hungatella hathewayi and Clostridium symbiosum, as well as pks-negative Escherichia coli, were enriched in those with no neoplastic findings, suggesting that in a FIT-positive population their presence may reflect other conditions causing intestinal bleeding rather than underlying neoplasia. Microbial profiles were predominantly associated with distal rather than proximal lesions. Together, our findings highlight the potential for microbial markers to improve FIT-based CRC screening, especially by differentiating those with premalignant lesions from those who test FIT-positive for other reasons.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerGastrointestinal MicrobiomeAgedBacteriaFecesFemaleHumansMaleMass ScreeningMetagenomeMiddle AgedNorwayOccult BloodPrecancerous Conditions

Identifiers

PMID42642381
PMCPMC13507204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.